Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Initiates Coverage On Fortinet with Neutral Rating

Guggenheim Initiates Coverage On Fortinet with Neutral Rating

Guggenheim analyst Raymond McDonough initiates coverage on Fortinet (NASDAQ:FTNT) with a Neutral rating.

byBenzinga Newsdesk

January 24, 2023

1 minute read

Guggenheim analyst Raymond McDonough initiates coverage on Fortinet (NASDAQ:FTNT) with a Neutral rating.

Analyst Ratings

Expert Ratings for Webster Finl

By Benzinga Insights

October 4, 2:00 PM

Webster Finl (NYSE:WBS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

WBS

Enviva Partners Q2 Sales $296.30M Beat $286.26M Estimate

By Michael Horton

August 3, 4:23 PM

Enviva Partners (NYSE:EVA) reported quarterly sales of $296.30 million which beat the analyst consensus estimate of $286.26 million by 3.51 percent. This is a 3.95 percent increase over sales of $285.04 million the same

EVA

Analyst Foresees Single-Digit Volume Growth For Vital Farms Amid Bird Flu Induced Supply Shortage

By Shivani Kumaresan

Today, 2:57 PM

Needham analyst Matt McGinley reiterated a

VITL

News

BriaCell Therapeutics Granted U.S. Patent# 11559574: Whole-cell Cancer Vaccines And Methods For Selection Thereof

By Charles Gross

January 24, 11:13 AM

https://www.scribd.com/document/621627063/BCTX-Patent

BCTX

Guggenheim Initiates Coverage On Fortinet with Neutral Rating

Related Posts

Expert Ratings for Webster Finl

Enviva Partners Q2 Sales $296.30M Beat $286.26M Estimate

Analyst Foresees Single-Digit Volume Growth For Vital Farms Amid Bird Flu Induced Supply Shortage

BriaCell Therapeutics Granted U.S. Patent# 11559574: Whole-cell Cancer Vaccines And Methods For Selection Thereof